Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Overview of Dataderm, MIPS, and the Evolution of Dermatology Quality Reporting
Description
The speaker, a private-practice dermatologist and longtime Dataderm user, gave an overview of how U.S. quality reporting evolved from early voluntary incentive programs to the current Quality Payment Program under MACRA, which created MIPS and expanded qualified clinical data registries like Dataderm. She explained that MIPS adjusts Medicare Part B payments based on four areas—quality, improvement activities, promoting interoperability, and cost—and noted that dermatology-specific measures through Dataderm can make reporting more relevant to daily practice. She also described the newer MIPS Value Pathways as a CMS direction toward specialty-focused reporting, while emphasizing that Dataderm now supports both traditional MIPS and MVP reporting. The talk then traced Dataderm’s origins in 2016 as the AAD’s response to the lack of dermatology-relevant measures, highlighting its goals of enabling reporting, building a large data asset for outcomes research and benchmarking, and supporting value-based care. She reviewed Dataderm’s growth, its annual reporting and research uses, and the recent transition to a new AAD-owned platform to improve flexibility, EHR compatibility, data ownership, and customer support. Looking ahead, she said Dataderm aims to strengthen user-friendly dashboards, research capabilities, advocacy, and future quality development beyond MIPS.
View moreConclusions
- DataDerm appears to have successfully filled a major gap by giving dermatologists specialty-relevant quality measures and a registry built around dermatology practice rather than primary-care metrics.
- The program seems effective for MIPS reporting, with the presentation emphasizing that the reporting workflow is relatively straightforward once practices are enrolled.
- DataDerm has grown into a very large dermatology registry, suggesting strong participation and substantial real-world data coverage across practices and patients.
- The registry’s data are diverse enough to support benchmarking, outcomes research, and practice improvement, not just payment reporting.
- The transition to a new AAD-owned platform seems intended to make DataDerm more flexible, more technologically current, and less dependent on third-party vendor limitations.
- A key conclusion is that owning the platform and data is viewed as strategically important for the Academy and for future registry sustainability.
- DataDerm is being positioned to support the shift from traditional MIPS toward MIPS Value Pathways while still allowing members to report through either route during the transition.
- The presentation suggests that better customer support, improved EHR recognition, and more interactive analytics are important quality-of-life improvements for users.
- Beyond reimbursement, DataDerm is increasingly presented as a research infrastructure that can generate publishable real-world evidence for dermatology.
- Overall, the talk concludes that DataDerm is evolving from a reporting tool into a broader platform for quality improvement, research, advocacy, and demonstrating dermatology’s value in future payment models.
- Tax Relief and Health Care Act of 2006; Physician Quality Reporting Initiative (PQRI), a voluntary reporting program with a 1.5% incentive.#10.2165/00115677-200614030-00001
- Medicare Improvement for Patients and Providers Act of 2008 increased the PQRI incentive to 2% and made public reporting mandatory.
- Affordable Care Act (March 23, 2010).
- Medicare Access and CHIP Reauthorization Act of 2015 (MACRA), which established the Quality Payment Program and expanded/formalized the Qualified Clinical Data Registry (QCDR).
- DataDerm Annual Report under review with JAAD.
- JAAD publication topics: visit complexity in scarring versus non-scarring alopecia; underutilization of patch testing for contact dermatitis; rural-urban disparities in biologics and non-steroidal topicals for inflammatory skin conditions; higher odds of dupilumab prescriptions for Black patients with atopic dermatitis.